The Diversity of the Microbiome Impacts Chronic Lymphocytic Leukemia Development in Mice and Humans
Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: A prospective real-world study in Chinese cohort
Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first line ibrutinib: a nationwide registry study from the Italian Medicines Agency
Venetoclax consolidation in high-risk CLL treated with ibrutinib for ≥1 year achieves a high rate of undetectable MRD
Influence of Racial and Ethnic Identity on Overall Survival in Patients with Chronic Lymphocytic Leukemia
High-throughput proteomics identifies THEMIS2 as independent biomarker of treatment-free survival in untreated CLL
Ibrutinib in combination with rituximab is highly effective in treatment of steroid refractory autoimmune hemolytic anemia